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ABSTRACT
Objectives: Research is lacking on the correlation
between treatment satisfaction and conﬁdence, self-
esteem, and relationships for men receiving treatment for
erectile dysfunction (ED). We sought to correlate scores
between the validated Erectile Dysfunction Inventory of
Treatment Satisfaction (EDITS) index and the validated
Self-Esteem And Relationship (SEAR) questionnaire fol-
lowing treatment with sildenaﬁl citrate (VIAGRA).
Methods: This study was based on an open-label, ﬂexi-
ble-dose trial of 93 sildenaﬁl-naive patients with ED.
Pearson correlation coefﬁcients between EDITS index and
SEAR questionnaire scores, each of which can range from
0 to 100 (most favorable), were calculated at end of treat-
ment (EOT). An analysis of covariance model was applied
to associate changes from baseline to EOT in SEAR scores
with EDITS score at EOT, controlling for baseline SEAR
score.
Results: Signiﬁcant and sizable Pearson’s correlations
between SEAR and EDITS scores (P ≤ 0.0001; range:
0.49–0.84) were observed. A 10-point higher EDITS
scores at EOT corresponded to a signiﬁcant and tangible
average improvement in SEAR scores from baseline to
EOT (P ≤ 0.0001; range: 6.6–8.7). Average SEAR scores
at EOT were markedly different between patients
with greater treatment satisfaction at EOT (EDITS
score ≥ median EDITS score of 88.6; n = 50) and those
with lesser treatment satisfaction at EOT (EDITS score
<88.6; n = 43).
Conclusions: The data add to the validity of the SEAR
questionnaire, suggest a tangible relationship between
treatment satisfaction and psychosocial beneﬁt among
men with ED treated with sildenaﬁl, and highlight the
importance of assessing the psychosocial impact of ED in
men undergoing treatment.
Keywords: conﬁdence, erectile dysfunction, psychomet-
rics, quality of life, relationships, self-esteem, sildenaﬁl
citrate, Viagra.
Introduction
Erectile dysfunction (ED) is deﬁned as the inability
to achieve or maintain an erection sufﬁcient for sex-
ual intercourse [1], and is a prevalent condition
affecting as many as 50% of men over the age of
40 years [2]. The incidence of ED increases substan-
tially with age, approximately doubling with each
decade of life after 50 years [2]. ED is a common
complication of spinal cord injury and prostate sur-
gery [3,4]; is often a comorbid condition of diabe-
tes, depression, and other diseases [5–9]; and may
be a symptom of underlying, chronic systemic vas-
cular disease [10–12]. Nevertheless, ED is often
undertreated [13]. Moreover, men are often reluc-
tant or embarrassed to discuss sexual issues [14],
making diagnosis and treatment a challenge for
health-care providers.
Sexual and erectile function are considered
important components of men’s overall health [15].
The psychosocial impact of ED can lead to depres-
sion, loss of self-esteem, and relationship and mar-
ital difﬁculties [16]. A review of clinical trials
showed that successful ED treatment was associated
with improved sexual, relational, and emotional
aspects of the lives of patients with ED, regardless
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of the speciﬁc therapy used [16]. Three of these
studies assessed the impact of sildenaﬁl in a double-
blind placebo-controlled setting [3,17,18]. Sildena-
ﬁl was signiﬁcantly associated with clear
improvements in several components of sexual
function (ability to achieve and maintain an erec-
tion, sexual satisfaction), mental health (well-being,
depression, anxiety), and “quality of life” after suc-
cessful treatment of ED [18,19]. Thus, assessing the
psychosocial impact of ED is relevant toward
understanding and measuring sexual, relationship,
and emotional domains of treatment outcomes of
interest to patients.
More recently, three independent clinical trials
with sildenaﬁl—one an open-label trial [20] and
two double-blind placebo-controlled studies
[21,22]—have demonstrated major psychosocial
gains in self-esteem, conﬁdence, and relationships as
measured by the Self-Esteem and Relationship
(SEAR) questionnaire, an ED-speciﬁc instrument
that has undergone rigorous development and vali-
dation [20,23]. Focus groups of men with ED, their
female partners, and physicians, along with the clin-
ical literature, have provided testimony that
improved self-esteem, conﬁdence, and relationships
add value to health in men with ED [23]. The three
studies [20–22] also demonstrated uniformly large
gains in erectile and sexual functioning. For exam-
ple, in the open-label trial [20], mean scores for the
erectile function domain of the International Index
of Erectile Function (IIEF) (range: 1 [lowest] to 30
[highest]) increased signiﬁcantly from 15.5 (SD 6.4)
at baseline to 25.6 (SD 6.8) at end of treatment
(EOT) (P = 0.0001); the remaining four domains on
the IIEF also showed considerable improvement.
Changes in Erectile Function domain score corre-
lated moderately with changes in SEAR domain and
subscale scores (Sexual Relationship, r = 0.69; Con-
ﬁdence, r = 0.48; Self-Esteem, r = 0.47; Overall
Relationship, r = 0.35; P ≤ 0.001).
The Erectile Dysfunction Inventory of Treatment
Satisfaction (EDITS), another well-validated ED-
speciﬁc instrument, was developed to assess satis-
faction with ED therapies and to explore the impact
of patient and partner satisfaction on treatment
continuation [24]. EDITS has been used to evaluate
patients’ satisfaction with therapies such as sildena-
ﬁl, apomorphine, intracavernosal injections, and
penile prosthesis [25–27] for the treatment of ED of
varied etiologies, including Peyronie’s disease [28]
and following therapy for prostate cancer [29].
To fully assess how ED therapy affects a patient’s
condition, we need to consider different question-
naires each intended to measure a different aspect of
how ED therapy affects a patient’s proﬁle. Efﬁcacy
assessments of ED therapies like the IIEF primarily
focus on the patient’s erection and associated sexual
functioning. Treatment satisfaction measures like
the EDITS focus on treatment satisfaction, a char-
acteristic feature of ED therapy. Measures like the
SEAR questionnaire focus on the broader psycho-
social impact of the condition.
Research is lacking, however, on the association
between treatment satisfaction and improvements
in psychosocial factors following a beneﬁcial inter-
vention for ED. Treatment satisfaction is critical
in helping to prevent therapy discontinuation for
patients with ED [30,31]. A tangible association
between treatment satisfaction and psychosocial
factors like self-esteem, conﬁdence, and relation-
ships may suggest that these factors are also rele-
vant for treatment adherence. We therefore
investigated the relationship between the EDITS
index and the SEAR questionnaire in patients
treated with a beneﬁcial intervention for ED.
Methods
Study Design
The current study was part of a larger investigation
to assess the responsiveness of change scores on the
SEAR questionnaire—and especially its self-esteem
subscale—in a multicenter, open-label, ﬂexible-dose
(25–100 mg) clinical trial in sildenaﬁl-naïve men
with ED [20]. Patients were 18 years or older, in a
stable relationship with a single partner, and had
clinically documented ED. Following a 2-week
screening phase, patients received sildenaﬁl (initial
dose 50 mg, adjustable to 100 mg or 25 mg based
on efﬁcacy and tolerability) to be taken as needed
for 10 weeks. Patients were excluded if they had sit-
ting hypotension (blood pressure <90/50 mm Hg)
or severe hypertension (blood pressure >170/
110 mm Hg) or signiﬁcant cardiovascular disease.
Patients were excluded if they were taking nitrates
or nitric oxide donors or CYP3A4 inhibitors, were
previously treated with sildenaﬁl, or were currently
taking any other treatment for ED. The study was
approved by an Institutional Review Board, was
conducted in accordance with Good Clinical Prac-
tice requirements, and in full compliance with the
most recent amendments of the World Medical
Assembly Declaration of Helsinki.
Efﬁcacy Measures
In this report we focused on the association
between treatment satisfaction as measured by the
EDITS index and psychosocial factors as measured
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by the SEAR questionnaire. The EDITS (patient
version) consists of 11 items, scored from 0 (low
satisfaction) to 4 (high satisfaction), and an EDITS
index score is calculated by multiplying the mean
score of all 11 items by 25, which yields a total
score ranging from 0 (lowest satisfaction) to 100
(highest satisfaction) (Table 1). The EDITS index
was administered only at EOT. We restricted atten-
tion to EDITS as reported by the patient and did
not consider the optional partner EDITS responses
because partner responses were too limited for
meaningful analysis.
The SEAR questionnaire is composed of two
domains, Sexual Relationship (items 1–8) and Con-
ﬁdence (items 9–14); the Conﬁdence domain is
decomposed into two subscales, Self-Esteem (items
9–12) and Overall Relationship (items 13 and 14)
(Table 2) [20,23]. Scores are determined by sum-
ming their respective items and transforming them
onto a 0–100 scale; higher scores indicate a more
favorable response. The SEAR questionnaire was
completed at baseline and EOT.
Statistical Analysis
Pearson correlation coefﬁcients between scores on
the EDITS index and the SEAR questionnaire were
computed at EOT. An analysis of covariance model
was applied to associate changes (baseline to EOT)
in SEAR score with EDITS score at EOT, control-
ling for baseline SEAR score. Descriptive proﬁles
with mean and 95% conﬁdence intervals on the
SEAR questionnaire at EOT were partitioned by the
median EDITS score at EOT. All analyses were per-
formed with SAS software (SAS Institute Inc. 1999,
Version 8, Cary, NC).
Results
Baseline Characteristics
A total of 101 patients enrolled in the study
(Table 3). Comorbid medical conditions included
borderline or mild hypertension (48%), hypercho-
lesterolemia (23%), unspeciﬁed hyperlipidemia
(16%), diabetes (14%), benign prostatic hyperpla-
sia (13%), esophagitis (12%), depression (9%),
and ischemic heart disease (8%). Of these
patients, 93 (92.1%) had taken at least one silde-
naﬁl dose and had at least one efﬁcacy evaluation
(EOT or time of discontinuation) and were
Table 1 The EDITS index (patient version)
1. Overall, how satisﬁed are you with this treatment?
2. During the past 4 weeks, to what degree has the treatment met your expectations?
3. How likely are you to continue using this treatment?
4. During the past 4 weeks, how easy was it for you to use this treatment?
5. During the past 4 weeks, how satisﬁed have you been with how quickly the treatment works?
6. During the past 4 weeks, how satisﬁed have you been with how long the treatment lasts?
7. How conﬁdent has this treatment made you feel about your ability to engage in sexual activity?
8. Overall, how satisﬁed do you believe your partner is with the effects of this treatment?
9. How does your partner feel about your continuing to use this treatment?
10. How natural did the process of achieving an erection feel when you used this treatment during the past 4 weeks?
11. Compared to before you had an erection problem how would you rate the naturalness of your erection when you used this treatment 
during the past 4 weeks in terms of hardness?
Response options are speciﬁc for each question:
0 = Very dissatisﬁed/Did not meet expectations/Very unlikely to continue/Very difﬁcult to use, etc.
4 = Very satisﬁed/Completely met expectations/Very likely to continue/Very easy to use, etc.
The EDITS index is calculated by multiplying the mean score of all 11 items by 25, which yields a total score ranging from 0 (lowest satisfaction) 
to 100 (highest satisfaction).
Table 2 The SEAR questionnaire
1. Sexual Relationship domain
During the past 4 weeks:
1). I felt relaxed about initiating sex with my partner.
2). I felt conﬁdent that during sex my erection would last long 
 enough.
3). I was satisﬁed with my sexual performance.
4). I felt that sex could be spontaneous.
5). I was likely to initiate sex.
6). I felt conﬁdent about performing sexually.
7). I was satisﬁed with our sex life.
8). My partner was unhappy with the quality of our sexual 
 relations.
2. Conﬁdence domain
2a. Self-Esteem subscale
9). I had good self-esteem.
10). I felt like a whole man.
11). I was inclined to feel that I am a failure.
12). I felt conﬁdent.
2b. Overall Relationship subscale
13). My partner was satisﬁed with our relationship in general
14). I was satisﬁed with our relationship in general.
Response options:
1 = Almost never/never
2 = A few times (much less than half the time)
3 = Sometimes (about half the time)
4 = Most times (much more than half the time)
5 = Almost always/always
Note: Questions 8 and 11 are reverse scored and all scores are transformed
onto a 0–100 scale so that a higher score indicates a more favorable response
to treatment for all 14 items.
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included in the intent-to-treat analysis of the
SEAR questionnaire.
Association between EDITS Index and 
SEAR Questionnaire
EDITS index scores at EOT showed moderate-to-
high correlations with SEAR questionnaire scores at
EOT, ranging from 0.49 with the Overall Relation-
ship subscale to 0.84 with the Sexual Relationship
domain of the SEAR questionnaire (Table 4); there-
fore, all correlations were tangible and, in addition,
statistically signiﬁcant (P ≤ 0.0001).
A 10-point higher EDITS score at EOT (e.g., a
patient with a score of 70 compared with another
patient with a score of 60) corresponded to a sta-
tistically signiﬁcant (P ≤ 0.0001) average improve-
ment in SEAR scores from baseline to EOT, ranging
from 6.6 with the Overall Relationship subscale to
8.7 with the Sexual Relationship domain (Fig. 1).
Variation in EDITS scores, along with variation in
baseline SEAR scores, accounted for a substantial
proportion of variation in changes in SEAR scores
(Sexual Relationship, r2 = 0.78; Conﬁdence,
r2 = 0.70; Self-Esteem, r2 = 0.70; Overall Relation-
ship, r2 = 0.63; Overall, r2 = 0.76).
The median EDITS score was 88.6. Descriptive
proﬁles of SEAR scores were markedly different
between patients with greater treatment satisfaction
(i.e., greater than or equal to the median EDITS
score of 88.6; n = 50) and those with lesser treat-
ment satisfaction (less than the median EDITS score
of 88.6; n = 43; Fig. 2). Similar results would be
obtained if the mean EDITS score of 82.6 (SD 18.9)
was used instead of the median EDITS score as the
cutoff score of central tendency. Inferential results
with an analysis of covariance model, adjusting for
corresponding baseline SEAR score, conﬁrmed sim-
ilar differences in mean SEAR scores between the
two groups of EDITS scores split at the median
EDITS score (P ≤ 0.0001).
Table 3 Patient characteristics at baseline (n = 101)
Age (year)
Mean ± SD (range) 55 ± 12 (27–81)
Race, n (%)
White 66 (65)
African American 26 (26)
Asian 1 (1)
Other 8 (8)
Duration of ED (year)
Mean ± SD (range) 4.6 ± 7.5 (0.2–53.5)
Primary etiology of ED, n (%)
Psychogenic 26 (26)
Organic 48 (48)
Mixed 26 (26)
Unknown 1 (1)
SEAR component (n = 93), mean ± SD
1. Sexual Relationship domain 42.1 ± 21.7
2. Conﬁdence domain 55.0 ± 25.5
2a. Self-Esteem subscale 51.6 ± 26.9
2b. Overall Relationship subscale 61.8 ± 29.9
3. Overall (total) score 47.6 ± 21.6
Figure 1 Relationship between EDITS
index at end of treatment and changes on
the SEAR questionnaire. Higher scores on
the EDITS questionnaire, indicating higher
levels of treatment satisfaction with sildena-
ﬁl, were associated with improvements on
all SEAR components. Data are the mean
improvement (from baseline to end of treat-
ment) in SEAR score for a 10-point higher
EDITS score at end of treatment. Error bar
represents 95% conﬁdence interval (CI),
n = 93.
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Table 4 Descriptive statistics and correlations on SEAR
questionnaire and EDITS index at end of treatment (n = 93)
SEAR components
SEAR score
(Mean ± SD)
Correlation
with EDITS*
1. Sexual Relationship domain (77.8 ± 21.1) 0.84
2. Conﬁdence domain (80.7 ± 21.2) 0.67
2a. Self-Esteem subscale (81.0 ± 22.4) 0.68
2b. Overall Relationship subscale (81.0 ± 24.4) 0.49
3. Overall score (78.9 ± 20.3) 0.79
*P ≤ 0.0001. EDITS score: mean ± SD = 82.6 ± 18.9.
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Discussion
Erectile dysfunction can diminish self-esteem, con-
ﬁdence, and relationships [20]. The inability to per-
form sexually can have a signiﬁcant negative impact
on overall health and aspects of quality of life [32].
The World Health Organization includes emotional
and psychological well-being in its deﬁnition of
health [15], and normal sexual function is an
important component of men’s psychological well-
being and functioning. Conﬁrmatory evidence
indicates that successful treatment of ED improves
psychological and interpersonal relationships [33]
as well as quality of life [34].
Although questionnaires related to the SEAR
questionnaire have merit [33–36], a salient feature
of the SEAR questionnaire is its emphasis on con-
ﬁdence, relationship, and especially self-esteem
[20,23]. Three independent clinical trials suggest
that the SEAR questionnaire is robust in detecting
substantial changes related to relationships, conﬁ-
dence, and particularly self-esteem after  success-
ful treatment with sildenaﬁl [20–22]. Studies using
the EDITS index indicate its validity in measuring
patient satisfaction with different treatment
options for ED [25–27]. Because it measures inter-
related facets of treatment satisfaction, the multi-
item EDITS has better validity and reliability than
a single-item measure of treatment satisfaction
[24].
The current report is the ﬁrst to examine the
association between the EDITS index and the SEAR
questionnaire and, to our knowledge, the ﬁrst to
examine the association between a measure of treat-
ment satisfaction for ED therapy and an ED-speciﬁc
measure of psychological well-being and function-
ing. The data indicate a high correspondence of
treatment satisfaction with enhanced self-esteem,
conﬁdence, and relationship for sildenaﬁl-naïve
patients who were later given sildenaﬁl in an open-
label clinical trial. These results hold promise that,
like treatment satisfaction, improvements in self-
esteem, conﬁdence, and relationships may also be
an important consideration in maintaining long-
term therapy for ED.
Limitations of this single-treatment, open-label
study are the lack of placebo control and the lack of
blinding. These limitations might have predisposed
patients toward a successful study outcome, result-
ing in artiﬁcially high scores and correlations
between treatment satisfaction and psychosocial
indicators. Nevertheless, two subsequent rand-
omized, double-blind, placebo-controlled trials
[21,22] demonstrated that sildenaﬁl resulted in con-
siderable gains, above and beyond placebo, on the
SEAR   questionnaire   and   on   standard   measures
of clinical efﬁcacy like the IIEF [37]; correlations
between these standard measures and the SEAR
questionnaire were moderate to high in general
[21,22]. Although treatment satisfaction was not
assessed in those two randomized trials, it is quite
likely that treatment satisfaction would have main-
tained a high level of association with psychosocial
factors similar to that found in the open-label study,
given the relatively high level of interrelationships
among the EDITS index, the SEAR questionnaire,
the IIEF, and other measures of clinical efﬁcacy
obtained from existing studies.
Figure 2 Mean SEAR scores at end of
treatment, partitioned by median EDITS
score at end of treatment. The median score
was 88.6. Compared with patients who
reported lower levels of treatment satisfac-
tion (EDITS score < median EDITS score of
88.6; n = 43), patients who reported greater
treatment satisfaction (EDITS score ≥88.6;
n = 50) reported higher scores on all facets
of the SEAR questionnaire. Error bar repre-
sents 95% conﬁdence interval (CI), n = 93.
() Mean SEAR score among patients who
had an EDITS score equal to or greater than
the median score of 88.6 (n = 50); () mean
SEAR score among patients who had an
EDITS score less than the median score of
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Conclusions
The correlations between scores on the SEAR
questionnaire and the EDITS index are statistically
signiﬁcant and substantial. The data attest to a
moderate-to-high positive association between
treatment satisfaction and psychosocial beneﬁt
among men with ED treated with sildenaﬁl. Our
research has demonstrated an important triangle
among efﬁcacious treatment of ED (in erectile and
sexual function), treatment satisfaction (patients
like the way the treatment works for them), and
improvements in disease-speciﬁc parameters related
to quality of life. Psychosocial factors—self-esteem,
conﬁdence, and relationships—as measured by the
SEAR questionnaire, a disease-speciﬁc question-
naire for men with ED, show discernible separation
in the expected direction for varying levels of treat-
ment satisfaction, as measured by the EDITS index.
More satisfaction with ED treatment is associated
with more conﬁdence, more self-esteem, and better
relationships in men with ED. Further research is
encouraged to go beyond such an association to for-
mally examine a hypothesis of causality from treat-
ment satisfaction to improved psychosocial factors;
for such a purpose, structural equation models can
be employed in future studies. In the meanwhile, the
results of this study provide further evidence for the
validity of the SEAR questionnaire and highlight the
importance of assessing the psychosocial impact
of ED among men undergoing treatment for this
disorder.
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